DRUG

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a pre-clinical stage biotechnology company founded in 2019 and headquartered in Vancouver, Canada. The company went public in March 2021 and focuses on developing novel serotonin-based medicines for patients with severe neurological and psychiatric conditions. As a pre-clinical biotech firm, Bright Minds has not yet generated revenue from product sales and remains in the research and development phase of bringing potential treatments to market.